The effects of bariatric surgery on cardiac function: a systematic review and meta-analysis

Narek Sargsyan1, Jun Yu Chen2, Ravi Aggarwal2

  • 1Department of General Surgery, Imperial College Healthcare NHS Foundation Trust, London, UK. narek.sargsyan@nhs.net.

Insights

Bariatric surgery significantly improves cardiac structure and function in obese patients. This review shows positive changes in left ventricular mass, atrial diameter, and ejection fraction post-surgery.

Area of Science:

  • Cardiology
  • Metabolic Surgery
  • Cardiovascular Imaging

Background:

  • Obesity causes detrimental cardiac alterations, increasing cardiovascular risk.
  • Evidence suggests bariatric surgery can reverse these negative cardiac effects.

Approach:

  • Systematic review and meta-analysis of 80 studies involving 3332 patients.
  • Analyzed pre- and postoperative cardiac imaging parameters.

Key Points:

  • Significant reduction in left ventricular mass index (-12.2%).
  • Improved diastolic function (E/A ratio increase) and reduced left atrial diameter.
  • Enhanced left ventricular ejection fraction (+1.636%) and diastolic dimension.

Conclusions:

  • Bariatric surgery promotes reverse cardiac remodeling.
  • Improvements are linked to metabolic and hemodynamic changes post-surgery.
Abstract

Related Concept Videos

Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
674
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
826
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
342
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436